GlassScriptPhysician profile
Megan Dimoff
NPI 1033538483
$3,557.35
in general payments reported to CMS, 2019-2025
44 companies · $281 in 2025
The $281 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,061 · 2020: $234 · 2021: $901 · 2022: $316 · 2023: $409 · 2024: $356 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $985 · Consulting Fee: $60.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $985.13 |
| Consulting Fee | $60.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $465.66 | 2019-2021 | |
| Abbvie INC. | $289.13 | 2019-2024 | |
| Astellas Pharma US INC | $212.35 | 2019-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $191.14 | 2019-2025 | |
| Novo Nordisk INC | $191.08 | 2019-2024 | |
| Avion Pharmaceuticals | $167.15 | 2020-2023 | Balcoltra |
| Mylan Pharmaceuticals INC. | $156.32 | 2020-2022 | |
| Roche Diagnostics Corporation | $154.12 | 2019-2021 | |
| Therapeuticsmd, INC. | $117.09 | 2019-2022 | |
| Evofem Biosciences, INC. | $115.93 | 2021-2025 | Solosec, Phexx, Phexxi |
| Takeda Pharmaceuticals U.S.A., INC. | $114.60 | 2019-2024 | Trintellix |
| Sage Therapeutics, LLC | $111.31 | 2024-2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $106.38 | 2023-2025 | Myfembree |
| Davol INC. | $87.85 | 2021 | |
| Mayne Pharma Commercial LLC | $83.07 | 2023-2024 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $81.91 | 2019-2024 | Slynd |
| Currax Pharmaceuticals LLC | $66.67 | 2019-2021 | |
| Medtronic, INC. | $60.00 | 2023-2024 | |
| Coopersurgical, INC. | $56.49 | 2023 | Mara Console, Paragard T 380a |
| Duchesnay USA Incorporated | $54.12 | 2019 | |
| Myovant Sciences INC. | $50.09 | 2021-2022 | |
| Channel Medsystems, INC. | $48.13 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $46.14 | 2020-2024 | Gardasil, Gardasil 9 |
| Shield Therapeutics INC | $39.64 | 2024 | |
| Organon LLC | $37.74 | 2022-2023 | Nexplanon |
| Supernus Pharmaceuticals, INC. | $36.64 | 2025 | Qelbree |
| Daiichi Sankyo INC. | $33.22 | 2019 | |
| Boston Scientific Corporation | $32.94 | 2022 | |
| Biom'Up France Sas | $32.35 | 2021 | |
| Pfizer INC. | $32.07 | 2023-2024 | |
| Exact Sciences Corporation | $31.41 | 2025 | The Cologuard Plus Collection Kit |
| Millicent US INC | $28.43 | 2019-2024 | Femring, Intrarosa |
| Nalpropion Pharmaceuticals LLC | $27.26 | 2019 | |
| Lsi Solutions INC | $27.01 | 2021 | |
| Hologic Sales and Service, LLC | $25.81 | 2020-2021 | |
| Axsome Therapeutics, INC. | $22.41 | 2023 | Auvelity |
| Mycovia Pharmaceuticals, INC. | $20.68 | 2023 | Vivjoa |
| Lilly USA, LLC | $17.40 | 2024 | Zepbound |
| Allergan, INC. | $17.08 | 2019 | |
| Z-Medica, LLC | $16.47 | 2019 | |
| Meditrina | $13.73 | 2023 | |
| Shire North American Group INC | $13.40 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.22 | 2019 | |
| Lupin INC. | $11.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Dimoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.